New Treatment for Overactive Bladder Wins Approval

	Tweet

The U.S. Food and Drug Administration has approved the new drug Vesicare (solifenacin succinate) to treat symptoms of overactive bladder, the drug’s makers said.

Overactive bladder (OAB) is a condition that causes the bladder muscle to contract while the organ is filling, rather than when it is full. People with the condition feel the urge to urinate more frequently, often without warning. OAB affects up to 20 million men and women in the United States, reported the drug’s makers, GlaxoSmithKline and Japan’s Yamanouchi Pharmaceutical Co.

Approval of Vesicare followed four 12-week trials involving more than 3,000 people with OAB symptoms, including the urge to urinate more frequently and the accidental leakage of urine, the companies said in a prepared statement. The most common side effects were dry mouth, constipation, and blurred vision.

RELATED STORIES:
Studies Review New Drug and Indications for Heated Chemotherapy   Painkiller Vioxx Often Taken at Too High Dose   Tamiflu can prevent mortality in mammals   FDA approves generic version of Effexor (venlafaxine)   Many don’t disclose foregoing drugs   Splenda ad campaign comes under fresh fire   Computational Method Predicts New Uses for Existing Medicines   Chinese drugs driving down generic prices   Celebrex Heart Risk Lower Than Vioxx   New Guidelines for Prescribing Opioid Pain Drugs Published   FDA approval for Gemzar for ovarian cancer   Anti-inflammatory Drugs May Do More Harm than Good in Tendinopathy

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]